Sanara shareholders approve MiMedx merger; HSR waiting period runs to Oct 15 after refiling

Sanara MedTech Inc.

Shareholders approved the merger with MiMedx at the Sept 30, 2026 special meeting: 6,372,989 votes for, 1,944 against and 36,494 abstained.
Advisory vote on merger-related executive compensation passed 5,841,470 for, 75,247 against and 494,710 abstained.
MiMedx withdrew and refiled its HSR notification Sept 15, 2026, starting a new 30-day waiting period expiring 11:59 p.m. ET Oct 15, 2026.
6,411,427 shares (69.78% of the 9,188,035 outstanding as of the Sept 1 record date) were present, so the adjournment proposal was not needed.
Merger Agreement dated July 29, 2026 calls for Mustang Merger Sub to merge into Sanara, which survives as a wholly-owned MiMedx subsidiary.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.